Back to News
Market Impact: 0.4
EQT Nears €9.6 Billion Deal for Molecular Testing Firm Qiagen
Source: Bloomberg
M&A & RestructuringHealthcare & Biotech
EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion), according to people familiar with the matter. The transaction would end years of takeover speculation involving the European molecular testing company; no terms beyond the reported value were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EQT0.20
QGEN0.30
More News
- QIAGEN reports Q3 sales of $548M, adjusted EPS of $0.65
- QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
- EQT Warns of Hidden Portfolio Risks
- Pigment raises $250M at $2.3B valuation in round led by EQT fund
- Futures orbit around SpaceX as Tesla merger talk cheers investors
- Elon Musk Thinks $3.5 Trillion Tesla-SpaceX Mashup Is a Good Idea